Aerovate Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2021 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Aerovate Therapeutics, Inc. quarterly Nonoperating Income (Expense) history and growth rate from Q3 2021 to Q3 2023.
  • Aerovate Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2023 was $1.81M, a 220% increase year-over-year.
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $1.81M +$1.24M +220% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $1.31M +$1.09M +485% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $1.12M +$1.01M +927% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q3 2022 $564K +$548K +3425% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $224K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $109K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q3 2021 $16K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.